Jiangsu Kanion PharmaceuticalLtd Management

Management criteria checks 4/4

Jiangsu Kanion PharmaceuticalLtd's CEO is Yongchun Yang, appointed in Apr 2021, has a tenure of 3.58 years. directly owns 0.037% of the company’s shares, worth CN¥3.00M. The average tenure of the management team and the board of directors is 2.3 years and 3.5 years respectively.

Key information

Yongchun Yang

Chief executive officer

CN¥758.6k

Total compensation

CEO salary percentage	n/a
CEO tenure	3.6yrs
CEO ownership	0.04%
Management average tenure	2.3yrs
Board average tenure	3.5yrs

Recent management updates

Recent updates

CEO

Yongchun Yang (51 yo)

3.6yrs

Tenure

CN¥758,600

Compensation

Mr. Yongchun Yang is General Manager at Jiangsu Kanion Pharmaceutical Co. Ltd. since April 9, 2021 and has been its Director since December 27, 2019. Mr. Yang served as Chief Marketing Officer and Deputy G...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Yongchun Yang	GM & Director	3.6yrs	CN¥758.60k	0.037% CN¥ 3.0m
Suocheng Jiang	Deputy Chief Accountant	1.8yrs	CN¥207.50k	0.0044% CN¥ 357.0k
Feipeng Xian	Deputy General Manager	1.4yrs	CN¥521.10k	0.0070% CN¥ 570.9k
Quan Liu	Deputy General Manager	4.9yrs	CN¥742.70k	0.025% CN¥ 2.0m
Yu Pan	Deputy GM & Market Development Center	2.7yrs	CN¥1.07m	0.025% CN¥ 2.0m
Yun Wu	Deputy General Manager	1.4yrs	CN¥637.00k	0.018% CN¥ 1.5m
Chuanlei Wang	Deputy General Manager	2.7yrs	CN¥710.40k	0.025% CN¥ 2.0m
Pan Peng	Secretary	less than a year	no data	no data

2.3yrs

Average Tenure

47.5yo

Average Age

Experienced Management: 600557's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Yongchun Yang	GM & Director	4.9yrs	CN¥758.60k	0.037% CN¥ 3.0m
Wei Xiao	Chairman	24yrs	CN¥2.39m	2.99% CN¥ 242.8m
Zhenzhong Wang	Vice Chairman of the Board	8.2yrs	CN¥1.03m	0.037% CN¥ 3.0m
Meiling Jiang	Supervisor	1.4yrs	no data	no data
Min Xu	Independent Director	3.5yrs	CN¥100.00k	no data
Kaixian Chen	Independent Director	4.9yrs	CN¥100.00k	no data
Wu Di	Supervisor	2.5yrs	no data	no data
Xuebin Chen	Director	1.4yrs	CN¥641.10k	0.0098% CN¥ 799.4k
Lin Jiang	Supervisor	1.4yrs	no data	no data

3.5yrs

Average Tenure

51yo

Average Age

Experienced Board: 600557's board of directors are considered experienced (3.5 years average tenure).

Jiangsu Kanion PharmaceuticalLtd Management

Management criteria checks 4/4

Key information

Recent management updates

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

New minor risk - Earnings quality

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) agreed to acquire Jiangsu Zhongxin Medicine Co.,Ltd. from Jiangsu Kanion Group Co Ltd and Nanjing Kangzhu Enterprise Management Partnership (Limited Partnership) for CNY 270 million.

Investor sentiment improves as stock rises 15%

Third quarter 2024 earnings released: EPS: CN¥0.16 (vs CN¥0.14 in 3Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Investor sentiment improves as stock rises 17%

Second quarter 2024 earnings released: EPS: CN¥0.20 (vs CN¥0.22 in 2Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2024 Results on Jul 27, 2024

First quarter 2024 earnings released: EPS: CN¥0.26 (vs CN¥0.25 in 1Q 2023)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q1, 2024 Results on Apr 13, 2024

Investor sentiment improves as stock rises 18%

Jiangsu Kanion Pharmaceutical Co.,Ltd., Annual General Meeting, Apr 02, 2024

Full year 2023 earnings released: EPS: CN¥0.93 (vs CN¥0.75 in FY 2022)

Now 20% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. (SHSE:600557) announces an Equity Buyback for CNY 150 million worth of its shares.

Investor sentiment deteriorates as stock falls 17%

Now 23% undervalued after recent price drop

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Fiscal Year 2023 Results on Mar 11, 2024

New minor risk - Share price stability

Now 20% undervalued

Third quarter 2023 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 3Q 2022)

Investor sentiment deteriorates as stock falls 17%

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report Q3, 2023 Results on Oct 26, 2023

Investor sentiment improves as stock rises 19%

Second quarter 2023 earnings released: EPS: CN¥0.22 (vs CN¥0.18 in 2Q 2022)

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2023 Results on Jul 13, 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.19 in 1Q 2022)

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Full year 2022 earnings released: EPS: CN¥0.75 (vs CN¥0.56 in FY 2021)

Investor sentiment improves as stock rises 18%

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Now 21% undervalued

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.12 (vs CN¥0.081 in 3Q 2021)

Less than half of directors are independent

First quarter 2022 earnings released: EPS: CN¥0.19 (vs CN¥0.14 in 1Q 2021)

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.081 (vs CN¥0.08 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.10 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.14 (vs CN¥0.14 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.44 (vs CN¥0.86 in FY 2019)

Investor sentiment improved over the past week

New 90-day low: CN¥9.43

New 90-day low: CN¥10.99

New 90-day low: CN¥12.14

Third quarter earnings released

New 90-day low: CN¥12.29

New 90-day low - CN¥12.67

New 90-day low - CN¥12.93

First half earnings released

Jiangsu Kanion Pharmaceutical Co.,Ltd. to Report First Half, 2020 Results on Aug 20, 2020

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age